Replies to post #240175 on Biotech Values

[jbog]

Do you have any idea of what price increases have occurred and should be factored into these results.

[vinmantoo]

ABBV 3Q21 Mavyret sales=$426M, -3% QoQ:

That brings yearly sales to just under $1 billion so next quarter royalties will be at he 17% level. Hopefully Covid levels will remain depressed or even continue declining so it will no longer be a potential cause (excuse??) of lower than expected sales.

[DewDiligence]

4Q21 Mavyret sales were $427M, flat QoQ:

https://news.abbvie.com/news/press-releases/abbvie-reports-full-year-and-fourth-quarter-2021-financial-results.htm

The $427M consisted of: $197M US; $230M ex-US.

HCV new-patient starts, particularly in the US, are not (yet) back to pre-pandemic levels.

Full-year 2021 Mavyret sales were $1.71B.